Relationship between serum mi R-191,mi R-425 expression levels and XELOX chemotherapy sensitivity in patients with advanced gastric cancer
Objective To explore the relationship between the expression levels of serum micro RNA-191(mi R-191)and mi-cro RNA-425(mi R-425)and the sensitivity to XELOX chemotherapy in patients with advanced gastric cancer,aiming to provide a reference for clinical treatment decision-making.Methods A total of 104 patients with advanced gastric cancer who received XELOX regimen treatment at a hospital in Shaanxi from January 2021 to December 2023 were selected as the study participants.All patients received XELOX regimen treatment and were allocated to a sensitive group(36 cases)and a resistant group(68 cases)based on the therapeutic efficacy.The levels of serum mi R-191 and mi R-425 were detected before chemotherapy,and the clinical pathological data of all patients were collected.The receiver operating characteristic(ROC)curve was used to analyze the value of serum mi R-191 and mi R-425 in predicting the sensitivity of advanced gastric cancer patients to XELOX chemotherapy.Multivariate regression analysis was used to explore the influencing factors of XELOX chemotherapy sensitivity in these patients.Results The levels of serum mi R-191 and mi R-425 in the resistant group were significantly higher than those in the sensitive group(P<0.05).The area under the curve(AUC)(95%CI)for assessing the sensitivity of advanced gastric cancer patients to XELOX chemotherapy using serum mi R-191 and mi R-425 were 0.787(0.742-0.832)and 0.840(0.795-0.889),respectively,and the combined prediction AUC(95%CI)was 0.901(0.856-0.956).No significant differences were noted in age,gender,Eastern Cooperative Oncology Group performance status(ECOG score),tumor location,and pathological type between the sensitive and resistant groups(P>0.05).The propor-tion of poorly differentiated and stage Ⅳ patients in the resistant group was significantly higher than that in the sensitive group(P<0.05).regression analysis showed that TNM stage Ⅳ(OR=2.050,95%CI:1.241-3.386),low differentia-tion degree(OR=2.838,95%CI:1.437-5.602),serum mi R-191≥2.27(OR=6.228,95%CI:2.234-17.358),and serum mi R-425≥1.91(OR=5.078,95%CI:1.921-13.426)were risk factors for XELOX chemotherapy sensitivity in patients with advanced gastric cancer(P<0.05).Conclusion The expression levels of serum mi R-191 and mi R-425 are as-sociated with XELOX chemotherapy resistance in patients with advanced gastric cancer,and their combination has a high predictive value for the sensitivity of XELOX chemotherapy in these patients.
万方数据
维普
